IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation.

ABSTRACT: Immune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer but are only efficacious in a small subset of patients. Targeting suppressive mechanisms acting on innate immune cells could significantly improve the incidence of clinical response by facilitating a multi-lineage response against the tumor involving both adaptive and innate immune systems. Here, we show that intra-tumoral interleukin (IL)-38 expression is a feature of a large frequency of head and neck, lung and cervical squamous cancers and correlates with reduced immune cell numbers. We generated IMM20324, an antibody that binds human and mouse IL-38 proteins and inhibits the binding of IL-38 to its putative receptors, interleukin 1 receptor accessory protein-li

SUBMITTER: Dowling JP 

PROVIDER: S-EPMC10208126 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature